Effect of epidermal growth factor receptor tyrosine kinase inhibitor combined with 125I radioactive seed implantation in the treatment of non-small cell lung cancer
SHE Hua CHEN Kai
Department of Radiology, Affiliated Hospital of Xiangnan University, Hu′nan Province, Chenzhou 423000, China
Abstract：Objective To investigate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIS) combined with 125I radioactive seed implantation in the treatment of non-small cell lung cancer (NSCLC). Methods From June 2015 to May 2017, 70 patients with NSCLC from Department of Radiology, Affiliated Hospital of Xiangnan University were selected. According to the different treatment methods, they were divided into the control group (35 cases) and the observation group (35 cases). The patients in the control group were treated with EGFR-TKIS, and the observation group was treated with 125I radioactive seed implantation on the basis of the control group. The curative effect, the adverse reaction and the survival rate of the two groups were compared, and the Karnofsky performance starus score (KPS score) before and after treatment was compared. Results The effective rate and local control rate in the observation group were significantly higher than those in the control group (all P ＜ 0.05). There was no significant difference in pneumothorax, diarrhea, adverse reaction of skin and the rate of bone marrow suppression between the two groups (P ＞ 0.05). Follow-up was conducted for 30 months, 26 cases died in the control group and 18 cases in the observation group. The 1 year survival rate and 2 years survival rate in the observation group were significantly higher than those in the control group (P ＜ 0.05). The non-progression survival time was significantly higher than that in the control group (P ＜ 0.05). After 3 months of treatment, the Karlman score in the observation group was significantly higher than that in the control group (P ＜ 0.05). Conclusion EGFR-TKIS combined with 125I radioactive seed implantation can improve the therapeutic effect and local control rate of NSCLC patients, improve the 1 year and 2 years survival rate and progression-free survival time of patients, improve the quality of life of patients after treatment, and do not increase the risk of treatment.
[1] 张卉，张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志，2017，20（1）：61-65.
[2] Manegold C，Dingemans AC，Gray JE，et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC [J]. J Thorac Oncol，2017，12（2）：194-207.
[3] Diwanji TP，Mohindra P，Vyfhuis M，et al. Advances in radiotherapy techniques and delivery for non-small cell lung cancer：benefits of intensity-modulated radiation therapy，proton therapy，and stereotactic body radiation therapy [J]. Transl Lung Cancer Res，2017，6（2）：131.
[4] Li W，Zheng Y，Li Y，et al. Effectiveness of 125I seed implantation in the treatment of non-small cell lung cancer during R2 resection [J]. Oncology Letters，2017，14（6）：6690-6700.
[5] Abravan A，Eide HA，Knudtsen IS，et al. Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib [J]. Clin Transl Oncol，2017，4：57-63.
[6] 丁婕，戴旭，孟宪运，等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复，2015，22（9）：1150-1152.
[7] 李元明，刘文博，李超，等.恩度联合培美曲塞治疗中晚期非小细胞肺癌临床疗效及对患者生活质量的影响[J].山东医药，2017，57（22）：69-71.
[8] Rotow J，Bivona TG. Understanding and targeting resistance mechanisms in NSCLC [J]. Nature Reviews Cancer，2017，17（11）：637-658.
[9] 王亚旗，王兴，阎石，等.非小细胞肺癌新辅助治疗联合外科治疗的进展[J].中国肺癌杂志，2017，20（5）：352-360.
[10] 王敏，刘其礼，许帅，等.鸦胆子苦醇对非小细胞肺癌Nrf2-Notch1信号轴的影响机制研究[J].中国医药导报，2018，15（19）：16-19.
[11] 扶志敏，邝世晏，李炽光，等.非小细胞肺癌血清中IL-2、IL-6、TNF-α和IFN-γ变化与生存率相关性研究[J].中国现代医生，2019，57（11）：32-36.
[12] Duoji MM，Ciren BS，Long ZW，et al. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer：a network meta-analysis [J]. Oncotarget，2017，8（23）：37896-37911.
[13] 肖纬宇，吴格怡，刘洪，等.贝伐珠单抗对非小细胞癌患者肿瘤标志物的影响及其疗效观察[J].中外医学研究，2019，17（16）：54-55.
[14] Tomasini P，Brosseau S，Mazières J，et al. EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice [J]. Eur Respir J，2017，50（2）：1700514.
[15] Huo X，Huo B，Wang H，et al. Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage Ⅲ non-small cell lung cancer [J]. J Contemp Brachyther，2017，9（6）：527-534.
[16] Chapman BV，Farnia B，Ning MS，et al. （OA04） Patterns of Failure After Postoperative Radiation Therapy for Locally Advanced NSCLC：Implications for Shifting Toward More Conformal Radiation Fields [J]. Int J Radiat Oncol，2018，101（2）：E2-E3.
[17] Xiaodong H，Bin H，Lei W，et al. Implantation of Computed Tomography-Guided，125I Seeds in Combination with Chemotherapy for the Treatment of Stage Iii Nsclc [J]. Brachytherapy，2018，17（4）：S64.
[18] Song J，Fan X，Zhao Z，et al. 125I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care [J]. Onco targets Ther，2017，10：1345-1352.
[16] Zhang J，Wu N，Lian Z，et al. The Combined Antitumor Effects of125I Radioactive Particle Implantation and Cytokine-Induced Killer Cell Therapy on Xenograft Hepatocellular Carcinoma in a Mouse Model [J]. Technol Cancer Rest，2017，16（6）：1083-1091.
[17] Kobayashi K，Seike M，Zou F，et al. Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression [J]. Anticancer Res，2018，38（2）：753-762.
[18] Ashrafi S，Ahmadi S. Calculation of the low-energy gamma ray detection efficiency for a GM tube [J]. J Instrum，2017，12（6）：P06005.
[22] 陈文菊，吴书胜，何义富.化疗序贯EGFR-TKIs治疗晚期非小细胞肺癌的机制及疗效[J].现代肿瘤医学，2017， 25（11）：1844-1848.
[23] 孙颖，王宁，郭占文，等.125I放射性粒子植入联合放化疗治疗中晚期非小细胞肺癌的疗效观察[J].国际肿瘤学杂志，2017，44（10）：740-744.
2020, Vol. 17 
京公网安备 11010502046598号